Article Data

  • Views 430
  • Dowloads 153

Original Research

Open Access

The relationship between serum adropin levels and erectile dysfunction

  • Ercument Keskin1,*,
  • Ozgur Ekici2
  • Abdullah Erdogan2
  • Aliseydi Bozkurt1
  • Murat Sambel3
  • Mehmet Karabakan4
  • Cuma Mertoglu5,6

1Department of Urology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey

2Department of Urology, Bursa City Hospital, 16100 Bursa, Turkey

3Department of Urology, Antalya Training and Research Hospital, 07000 Antalya, Turkey

4Department of Urology, Toros State Hospital, 33010 Mersin, Turkey

5Department of Biochemistry, Faculty of Medicine İnönü University, 44050 Malatya, Turkey

6Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey

DOI: 10.22514/jomh.2024.091 Vol.20,Issue 6,June 2024 pp.58-63

Submitted: 04 February 2024 Accepted: 27 March 2024

Published: 30 June 2024

*Corresponding Author(s): Ercument Keskin E-mail: ekeskin@erzincan.edu.tr

Abstract

Erectile dysfunction (ED) is associated with endothelial damage, especially atheroscle-rosis. The search for biomarkers that can predict ED still continues. Adropin is known to affect nitric oxide (NO) bioavailability and energy homeostasis. In our study, we have aimed to investigate the relationship between serum adropin levels and ED. Male patients with and without ED between 40–60 years of age, who presented to the outpatient clinics of urology between November 2019–February 2020, were prospectively included in the study. Biochemical values measured at the time of admission to the outpatient clinic. According to the International Index of Erectile Function-5 (IIEF-5) scores which range between 5 and 25 points, patients with a score ≤21 were considered to have ED. The patients were divided into two groups: as ED and non-ED control groups. Laboratory values obtained at admission to outpatient clinics of urology were compared between groups. Patients with (n: 40), and without (n: 40) ED were included in the study. The mean age (50.2 ± 5.7 years), average body mass index (BMI) (29.7 ± 2.5 kg/m2), IIEF score (15.8 ± 6 pts), serum adropin (584.8 ± 172 pg/mL), and total testosterone (396.4 ± 91.7 ng/dL) levels were recorded. Serum adropin and testosterone levels were statistically significantly higher in the non-ED group than in the ED group (712.3 ± 222 pg/mL vs. 511.1 ± 145 pg/mL, p < 0.001 and 420.5 ± 56 ng/dL vs. 374.3 ± 98 ng/dL, respectively p = 0.032). Whereas fasting blood glucose (FBG) values were found to be statistically significantly higher in the ED group (100.2 ± 14 mg/dL vs. 143.8 ± 78 mg/dL, p = 0.001). According to the results of our study, serum levels of adropin which improves endothelial functions were comparatively lower in ED patients, as expected.


Keywords

Adropin; Biomarkers; Erectile dysfunction; Total testosterone


Cite and Share

Ercument Keskin,Ozgur Ekici,Abdullah Erdogan,Aliseydi Bozkurt,Murat Sambel,Mehmet Karabakan,Cuma Mertoglu. The relationship between serum adropin levels and erectile dysfunction. Journal of Men's Health. 2024. 20(6);58-63.

References

[1] Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology. 2010; 57: 804–814.

[2] Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nature Reviews Cardiology. 2022; 19: 59–74.

[3] Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology. 2022; 29: 5–15.

[4] Meakin PJ, Coull BM, Tuharska Z, McCaffery C, Akoumianakis I, Antoniades C, et al. Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. Journal of Clinical Investigation. 2020; 130: 4104–4117.

[5] Si Y, Feng Z, Liu Y, Fan W, Shan W, Zhang Y, et al. Inflammatory biomarkers, angiogenesis and lymphangiogenesis in epicardial adipose tissue correlate with coronary artery disease. Scientific Reports. 2023; 13: 2831.

[6] Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metabolism. 2008; 8: 468–481.

[7] Kolben Y, Weksler‐Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: implementing a personalized signature-based platform for chronotherapy. Obesity Reviews. 2021; 22: e13108.

[8] Bozic J, Kumric M, Ticinovic Kurir T, Males I, Borovac JA, Martinovic D, et al. Role of adropin in cardiometabolic disorders: from pathophysiological mechanisms to therapeutic target. Biomedicines. 2021; 9: 1407.

[9] Soori R, Amini AA, Choobineh S, Eskandari A, Behjat A, Ghram A, et al. Exercise attenuates myocardial fibrosis and increases angiogenesis-related molecules in the myocardium of aged rats. Archives of Physiology and Biochemistry. 2022; 128: 1–6.

[10] Ali II, D’Souza C, Singh J, Adeghate E. Adropin’s role in energy homeostasis and metabolic disorders. International Journal of Molecular Sciences. 2022; 23: 8318.

[11] Altamimi TR, Gao S, Karwi QG, Fukushima A, Rawat S, Wagg CS, et al. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019; 98: 37–48.

[12] Yang C, DeMars KM, Candelario-Jalil E. Age-dependent decrease in adropin is associated with reduced levels of endothelial nitric oxide synthase and increased oxidative stress in the rat brain. Aging and Disease. 2018; 9: 322.

[13] Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin-a novel biomarker of heart disease: a systematic review article. Iranian Journal of Public Health. 2016; 45: 1568–1576.

[14] Celik HT, Bilen M, Kazancı F, Yildirim ME, İncebay İB, Erdamar H. Serum adropin as a predictive biomarker of erectile dysfunction in coronary artery disease patients. Central European Journal of Urology. 2019; 72: 302–306.

[15] Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. International Journal of Molecular Sciences. 2018; 19: 1293.

[16] Zheng J, Liu M, Chen L, Yin F, Zhu X, Gou J, et al. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovascular Diagnosis and Therapy. 2019; 9: 1–7.

[17] Muhammed AA, Eid RMHM, Mohammed WS, Abdel-Fadeil MR. An association between adropin hormone and total testosterone in obese men: a case-control study. BMC Endocrine Disorders. 2022; 22: 192.

[18] Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, et al. Serum adropin levels are reduced in adult patients with nonalcoholic fatty liver disease. Medical Principles and Practice. 2019; 28: 463–469.

[19] Zhang H, Jiang L, Yang YJ, Ge RK, Zhou M, Hu H, et al. Aerobic exercise improves endothelial function and serum adropin levels in obese adolescents independent of body weight loss. Scientific Reports. 2017; 7: 17717.

[20] Brnić D, Martinovic D, Zivkovic PM, Tokic D, Tadin Hadjina I, Rusic D, et al. Serum adropin levels are reduced in patients with inflammatory bowel diseases. Scientific Reports. 2020; 10: 9264.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.9 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (https://kanalregister.hkdir.no/publiseringskanaler/Forside).

Submission Turnaround Time

Conferences

Top